Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana | Zendy

David Chadwick | Zendy; Michael Ankcorn | Zendy; Fred Stephen Sarfo | Zendy; Richard Odame Phillips | Zendy; Z. Fox | Zendy; Ana Garcia | Zendy; Lambert Appiah | Zendy; George BeduAddo | Zendy; Anna María Geretti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana

Author(s) -

David Chadwick,

Michael Ankcorn,

Fred Stephen Sarfo,

Richard Odame Phillips,

Z. Fox,

Ana Garcia,

Lambert Appiah,

George BeduAddo,

Anna María Geretti

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks333

Subject(s) - coinfection , hbsag , lamivudine , medicine , stavudine , nevirapine , hepatitis b virus , efavirenz , hepatitis b , gastroenterology , regimen , zidovudine , hbeag , context (archaeology) , viral load , virology , immunology , virus , antiretroviral therapy , viral disease , biology , paleontology

HIV/hepatitis B virus (HBV) coinfection is common in Ghana, where first-line antiretroviral therapy (ART) comprises lamivudine with zidovudine or stavudine and nevirapine or efavirenz. Little is known about ART outcomes in the context of coinfection. This study evaluated outcomes of ART among HIV/HBV-coinfected Ghanaians, focusing on locally available parameters.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research